Eli Lilly reaches new highs! JPMorgan raises Eli Lilly's target price! (In-depth)
Eli Lilly (LLY) stock reached a new high on July 8, 2026, with the most direct catalyst beingJPMorgan, a leading Wall Street investment bank, significantly raised its price target after market close on July 7.
1. Core Catalyst: JPMorgan Raises Price Target
JPMorgan analyst Chris Schott raised Eli Lilly’s price target from$1,300 to $1,400, maintaining an “Overweight” rating. This target is notably above Wall Street’s average of $1,243, implying about a17% upside from the July 6 closing price.
The analyst’s report clearly stated the bull-case logic for Eli Lilly is:
Continued ramp-up of Mounjaro internationally
Robust growth in the US obesity market
Projectedtotal sales this quarter to reach $20.7 billion (about $300 million above consensus),earnings per share (EPS) $8.85 (up $0.13)
2. Other Positive Signals from Wall Street Investment Banks
Prior to JPMorgan, other banks have already sent positive signals:
| Cantor Fitzgerald | Raised target from $1,230 to $1,350 , maintained “Overweight” | July 6 |
| RBC Capital | Reiterated “Outperform”, target stays at $1,250 | Recent |
| Leerink Partners | Previously raised target to $1,232 | Earlier |
Cantor Fitzgerald specifically stated that major biopharmaceutical companies are expected to report strong overall Q2 2026 results and may guide for higher full-year revenues.
3. Strong Growth Forecast for the GLP-1 Product Line
Investment bank reports generally emphasize that Eli Lilly’s growth driver is itsGLP-1 weight-loss drug product line:
Zepbound (obesity indication) maintaining strong demand in the US
Mounjaro (diabetes indication) continued expansion internationally
Oral drug orforglipron (Foundayo) andtriple-agonist retatrutide and other next-gen assets continue to raise market expectations
4. Additional Positive Factors in Recent Weeks
In recent weeks, Eli Lilly has accumulated several additional positives:
US Medicare GLP-1 Bridge Program: From July 1, 2026, eligible insured patients can access Zepbound and Foundayo with a copay of just $50/month, expected to greatly expand patient access
Cancer drug Jaypirca gains European support: The European Medicines Agency Committee for Medicinal Products for Human Use supports its use for chronic lymphocytic leukemia, paving the way for final EU approval
Sector rotation effect: On July 8, US equity markets saw funds rotate from chip stocks and other sectors to healthcare, with Eli Lilly as a leading pharma beneficiary
5. Fundamental Data Support
On a fundamental basis, Eli Lilly’s stock price has climbed about54%–58% over the past year, with a market cap reaching$1.1 trillion. Company revenue grew 47%, PEG ratio is only 0.33, and Piotroski Score reaches a perfect 9, reflecting robust financial health.
Summary: Eli Lilly’s record-high stock price is a result ofJPMorgan’s significant price target raise as a direct catalyst, combined withbroad bullishness from multiple investment banks,strong growth outlook for the GLP-1 pipeline, multiple recent positive developments andmarket sector rotation. The market will closely watchthe Q2 earnings to be released in August to validate analysts’ projections (sales of $20.7 billion, EPS of $8.85).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wall Street giants collectively raise rate hike forecasts, US Treasury futures continue to fall, gold drops over 1% to break 4000
After the US October CPI exceeded expectations, Goldman Sachs and Nomura added a forecast for an interest rate hike in March next year, while Deutsche Bank included a forecast for a rate hike in January next year. Currently, the market has fully priced in a 25 basis point rate hike in December, with a 13% probability for a 50 basis point hike. On Wednesday, the US Treasury spot market was closed, but Treasury futures continued to fall, with corresponding yields rising by about 2 to 4 basis points, and spot gold came under pressure, dropping by 1.1%.
No Need to Worry About the Cooling Down of AI Data Center Construction? The US Import Boom Is Unlikely to Subside in the Short Term, Real Impact May Come in 2029
It takes an average of 4.8 years from finalizing investment to starting construction of a data center project, and an additional 2.6 years from construction start to becoming operational. Servers usually cannot be installed until after the building structure and racks are completed. For trade partners such as Taiwan (China), South Korea, and Mexico who rely on US data center supply chain demand, the inertia in construction timelines provides at least a one- to two-year buffer for future exports.
Federal Reserve Major Debate: When Should the Tenure of “Number Three” Williams End?
The main point of contention is whether Williams should step down in June 2028, upon completing a full 10-year term, or in June 2027, when he reaches the mandatory retirement age of 65. Analysts point out that the Federal Reserve Board holds ultimate discretion; if he leaves early, Fed Chair Waller would be able to assert greater control over the appointment to this critical position. However, forcing Williams to shorten his term could easily be interpreted as political manipulation. Williams himself is expected to serve until June 2028.
Crypto prices
More
